Log In or Register to Join The Conversation!

This topic has 0 replies, 1 voice, and was last updated 2 years, 6 months ago by Michael Morale.

  • Author
    • #13237
      Michael Morale

      In this episode of the Morale Monologue, I’m giving everyone information regarding Avexis Pharmaceutical, and their announcement regarding their expansion of operations to North Carolina. Illinois-based AveXis, a Novartis company, is developing AVXS-101, a proprietary gene therapy that could prove to be a transformative treatment for babies and children with SMA types 1, 2 and 3. These treatments will also benefit adults with SMA in the coming future. AveXis is anticipated to invest about $55 million into the new facility and open up about 200 new jobs, giving a boost to the state’s economy while improving its capabilities to manufacture therapies targeting rare neurological and genetic diseases, including spinal muscular atrophy (SMA).

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?


Create Account

Copyright © 2017-2021 All rights reserved.